Management of glomerular proteinuria: a commentary - PubMed (original) (raw)
Review
Management of glomerular proteinuria: a commentary
William A Wilmer et al. J Am Soc Nephrol. 2003 Dec.
Abstract
It is widely accepted that proteinuria reduction is an appropriate therapeutic goal in chronic proteinuric kidney disease. Based on large randomized controlled clinical trials (RCT), ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB) therapy have emerged as the most important antiproteinuric and renal protective interventions. However, there are numerous other interventions that have been shown to be antiproteinuric and, therefore, likely to be renoprotective. Unfortunately testing each of these antiproteinuric therapies in RCT is not feasible. The nephrologist has two choices: restrict antiproteinuric therapies to those shown to be effective in RCT or expand the use of antiproteinuric therapies to include those that, although unproven, are plausibly effective and prudent to use. The goal of this work is to provide the documentation needed for the nephrologist to choose between these strategies. This work describes 25 separate interventions that are either antiproteinuric or may block injurious mechanisms of proteinuria. Each intervention is assigned a level of recommendation (Level 1 is the highest; Level 3 is the lowest) according to the strength of the evidence supporting its antiproteinuric and renoprotective efficacy. Pathophysiologic mechanisms possibly involved are also discussed. The number of interventions at each level of recommendation are: Level 1, n = 7; Level 2, n = 9; Level 3, n = 9. Our experience indicates that we can achieve in most patients the majority of Level 1 and many of the Level 2 and 3 recommendations. We suggest that, until better information becomes available, a broad-based, multiple-risk factor intervention to reduce proteinuria can be justified in those with progressive nephropathies. This work is intended primarily for clinical nephrologists; therefore, each antiproteinuria intervention is described in practical detail.
Comment in
- Regarding: "Management of glomerular proteinuria: a commentary".
Brenner BM. Brenner BM. J Am Soc Nephrol. 2004 May;15(5):1354-5; discussion 1356-7. J Am Soc Nephrol. 2004. PMID: 15100378 Review. No abstract available.
Similar articles
- Renoprotection: one or many therapies?
Hebert LA, Wilmer WA, Falkenhain ME, Ladson-Wofford SE, Nahman NS Jr, Rovin BH. Hebert LA, et al. Kidney Int. 2001 Apr;59(4):1211-26. doi: 10.1046/j.1523-1755.2001.0590041211.x. Kidney Int. 2001. PMID: 11260381 Review. - Renal damage associated with proteinuria.
Praga M, Morales E. Praga M, et al. Kidney Int Suppl. 2002 Dec;(82):S42-6. doi: 10.1046/j.1523-1755.62.s82.9.x. Kidney Int Suppl. 2002. PMID: 12410854 Review. - Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
Esnault VL, Ekhlas A, Nguyen JM, Moranne O. Esnault VL, et al. Nephrol Dial Transplant. 2010 Jul;25(7):2218-24. doi: 10.1093/ndt/gfp776. Epub 2010 Jan 26. Nephrol Dial Transplant. 2010. PMID: 20106824 Clinical Trial. - Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C, Conte G. Catapano F, et al. Am J Kidney Dis. 2008 Sep;52(3):475-85. doi: 10.1053/j.ajkd.2008.03.008. Epub 2008 May 12. Am J Kidney Dis. 2008. PMID: 18468748
Cited by
- Effect of age, sex, and chronic kidney disease on urinary creatinine excretion in Japanese patients.
Yasui S, Horino T, Mitani K, Terada Y, Okuhara Y, Hatakeyama Y. Yasui S, et al. Clin Exp Nephrol. 2024 Sep 27. doi: 10.1007/s10157-024-02569-5. Online ahead of print. Clin Exp Nephrol. 2024. PMID: 39331318 - Adiponectin C1q/Tumor Necrosis Factor-Related Protein 13 (CTRP13) Protects against Renal Inflammation and Fibrosis in Obstructive Nephropathy.
Li Y, Wang W, Liu C, Zeng M, Xu L, Du R, Wang C. Li Y, et al. Biomedicines. 2023 Dec 25;12(1):51. doi: 10.3390/biomedicines12010051. Biomedicines. 2023. PMID: 38255158 Free PMC article. - Machine-learning enhancement of urine dipstick tests for chronic kidney disease detection.
Jang EC, Park YM, Han HW, Lee CS, Kang ES, Lee YH, Nam SM. Jang EC, et al. J Am Med Inform Assoc. 2023 May 19;30(6):1114-1124. doi: 10.1093/jamia/ocad051. J Am Med Inform Assoc. 2023. PMID: 37027837 Free PMC article. - Role of hypertension in progression of pediatric CKD.
Mitsnefes MM, Wühl E. Mitsnefes MM, et al. Pediatr Nephrol. 2023 Nov;38(11):3519-3528. doi: 10.1007/s00467-023-05894-1. Epub 2023 Feb 3. Pediatr Nephrol. 2023. PMID: 36732375 Review. - Association of Dipstick Proteinuria with Long-Term Mortality among Patients with Hypertensive Crisis in the Emergency Department.
Kim BS, Yu MY, Park JK, Shin J, Shin JH. Kim BS, et al. J Pers Med. 2022 Jun 14;12(6):971. doi: 10.3390/jpm12060971. J Pers Med. 2022. PMID: 35743755 Free PMC article.
Publication types
MeSH terms
Grants and funding
- M01 RR 00034/RR/NCRR NIH HHS/United States
- P01 DK 55546/DK/NIDDK NIH HHS/United States
- U01 DK 39485/DK/NIDDK NIH HHS/United States
- U10 DK 48621/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Miscellaneous